It will be a laboratory with an initial capacity of five thousand tests. It will serve residents of the Jelenia Góra and Legnica regions.

Similar facilities currently operate exclusively in Wrocław, but they are not efficient enough for patients from Bolesławiec to receive their results within 24 hours. Meanwhile, the speed of tests confirming or ruling out coronavirus infection is of exceptional importance.

The time devoted to diagnosis and initiating treatment for patients will be significantly reduced, which should increase the number of available hospital beds. There are currently no vacant beds at the Bolesławiec facility, which has been converted into a single-specialty infectious diseases hospital.

Thanks to rapidly performed tests, patients suspected of being infected who are waiting for their results and require hospitalization, for example because of internal medicine or neurological conditions, could be transported to other hospitals if their tests prove negative.

The Bolesławiec laboratory will issue results in less than 24 hours from the time the samples are collected. As the hospital director, Kamil Barczyk, says, around 100–150 tests are currently being performed each day. That is the level of demand.

The tests to be performed in Bolesławiec are manufactured in the USA. Their reliability is 99 percent. The director estimates that a package of five thousand tests will be sufficient for four months of operation. The diagnosticians have expressed their willingness to undergo additional training and work with the new equipment.

In addition to the tests, the hospital will receive modern diagnostic equipment, also imported from the USA, along with laminar-flow hoods, centrifuges, extractors, reagents, disposable materials and other items. Installing such advanced laboratory diagnostics also requires construction work, which is already nearing completion. The laboratory is intended to serve for many years, not only during the coronavirus pandemic. The equipment can also diagnose other infections, such as HIV and viral hepatitis.

The total cost of the investment is PLN 1,500,000. Around 50 percent of the expenditure will be covered by the European Union through the Marshal's Office of the Lower Silesian Voivodeship; the remainder will come from local-government grants and the hospital's own funds.